123 related articles for article (PubMed ID: 31243213)
1. Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX.
Sasaki K; Zhou Q; Matsumoto Y; Saiki T; Moriyama M; Saijo Y
Intern Med; 2019 Oct; 58(19):2791-2795. PubMed ID: 31243213
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Terazawa T; Matsuyama J; Goto M; Kawabata R; Endo S; Imano M; Fujita S; Akamaru Y; Taniguchi H; Tatsumi M; Lee SW; Kurisu Y; Kawakami H; Kurokawa Y; Shimokawa T; Sakai D; Kato T; Fujitani K; Satoh T
Oncologist; 2020 Feb; 25(2):119-e208. PubMed ID: 32043772
[TBL] [Abstract][Full Text] [Related]
3. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
4. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
5. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.
Kim ST; Lee J; Lee SJ; Park SH; Jung SH; Park YS; Lim HY; Kang WK; Park JO
Oncotarget; 2016 Apr; 7(17):24088-96. PubMed ID: 27003363
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Thrombocytopenia Induced by Capecitabine Plus Oxaliplatin Therapy in Patients With Colorectal Cancer.
Kato N; Nakai T; Kodama S; Koyama S; Nakane S; Wada Y; Oda H; Katayama H; Mase H; Miyagawa Y; Miyazaki M; Yamada S; Yamada K
In Vivo; 2024; 38(3):1243-1252. PubMed ID: 38688620
[TBL] [Abstract][Full Text] [Related]
7. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Lui A; Mulder K; Brezden-Masley C; Vickers M; Monzon J; Kennecke H; Goel R; Vos L; Ghosh S; Marginean H; Fields A; Maroun J; Spratlin J
Invest New Drugs; 2018 Aug; 36(4):674-682. PubMed ID: 29725881
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the Usefulness of Pharmaceutical Outpatient Clinic for Gastric Cancer Patients Receiving Capecitabine plus Oxaliplatin as Postoperative Adjuvant Chemotherapy].
Okuda Y; Mikame Y; Sato R; Shinada M; Saito T; Kezuka C; Wakamori M; Aoki R; Kano S; Sanbe R; Otsuka Y; Nakazawa T; Yamaguchi H; Imai Y
Gan To Kagaku Ryoho; 2022 Sep; 49(9):963-967. PubMed ID: 36156015
[TBL] [Abstract][Full Text] [Related]
9. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
10. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
12. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
[TBL] [Abstract][Full Text] [Related]
13. [CapeOX Therapy as a Salvage Treatment for Advanced Gastric Cancer Refractory to S-1, Cisplatin, Irinotecan, and Taxanes].
Okagawa Y; Sagawa T; Sakurada A; Uemura N; Hamaguchi K; Tamura F; Fujikawa K; Takahashi Y
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1615-1618. PubMed ID: 30449849
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
Satake H; Kondo M; Mizumoto M; Kotake T; Okita Y; Ogata T; Hatachi Y; Yasui H; Miki A; Imai Y; Ichikawa C; Murotani K; Kotaka M; Kato T; Kaihara S; Tsuji A
Anticancer Res; 2017 Jul; 37(7):3703-3710. PubMed ID: 28668863
[TBL] [Abstract][Full Text] [Related]
15. Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.
Chin K; Takahari D; Kawabata R; Hosaka H; Saitou SO; Shiraishi T; Yabusaki H; Goto M; Nakamura M; Imamura H; Shindo Y; Nagashima F; Ichikawa W; Saotome T; Yamamoto W; Ishizuka N; Yamaguchi K
Anticancer Res; 2022 May; 42(5):2683-2687. PubMed ID: 35489762
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
17. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
Hofheinz RD; Wenz F; Lukan N; Mai S; Kripp M; Staiger W; Schwarzbach M; Willeke F; Möhler M; Post S; Hochhaus A
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):142-7. PubMed ID: 18539404
[TBL] [Abstract][Full Text] [Related]
19. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
[TBL] [Abstract][Full Text] [Related]
20. Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.
Leichman L; Pendyala L; Leichman CG
Semin Oncol; 2003 Aug; 30(4 Suppl 11):11-8. PubMed ID: 14506599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]